Investing.com — Shares of Esperion (NASDAQ:) Therapeutics (NASDAQ:ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, 2025 In a presentation at the 43rd annual JP Morgan Healthcare Conference held on January 15, 2025, Esperion projected that research and development costs would be between $55. million and $65 million and the costs of selling, general and administrative expenses will range between 160 and 170 million dollars.
The updated financial guidance indicates that the company anticipates operating expenses will total between $215 million and $235 million for the year. This forecast represents a significant increase in the company's spending, which has caused the current share value to decline as investors react to the potential impact on Esperion's financial position.
Esperion's announcement has been a key factor in today's trading session, with the higher end of the operating expense range being especially notable to investors. Increased projected expenses may raise concerns about the company's cost management and its effects on profitability in the coming year.
While the company did not provide specific reasons for the expected increase in expenses, research and development and sales, general and administrative costs are typical areas of investment for pharmaceutical companies like Esperion. These investments are often necessary for the development of new drugs and the expansion of market reach for existing products.
This article was generated with the support of ai and reviewed by an editor. For more information consult our T&C.
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=();t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e)(0);s.parentNode.insertBefore(t,s)}(window, document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
